SAR446523 Granted Orphan Drug Designation for Patients With Relapsed, Refractory Multiple Myeloma

FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for relapsed/refractory multiple myeloma.

SAR446523 Granted Orphan Drug Designation for Patients With Relapsed, Refractory Multiple Myeloma

Sanofi's SAR446523 receives orphan drug designation for relapsed refractory multiple myeloma, enhancing treatment options and patient outcomes.

Novel GPRC5D mAB Receives FDA Orphan Drug Designation in R/R Myeloma

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted monoclonal antibody approach.

FDA Grants Orphan Drug Designation to GPRC5D Target in Multiple Myeloma

SAR446523 is currently being evaluated in a first-in-human, phase 1 trial in patients with pretreated relapsed/refractory multiple myeloma.